Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study.
BACKGROUND
Severe sepsis is common and frequently fatal, and community-acquired pneumonia (CAP) is the leading cause. Although severe sepsis is often attributed to uncontrolled and unbalanced inflammation, evidence from humans with infection syndromes across the breadth of disease is lacking. In this study we describe the systemic cytokine response to pneumonia and determine if specific patterns, including the balance of proinflammatory and anti-inflammatory markers, are associated with severe sepsis and death.


METHODS
This is a cohort study of 1886 subjects hospitalized with CAP through the emergency departments in 28 US academic and community hospitals. We defined severe sepsis as CAP complicated by new-onset organ dysfunction, following international consensus conference criteria. We measured plasma tumor necrosis factor, IL-6 (interleukin 6), and IL-10 levels daily for the first week and weekly thereafter. Our main outcome measures were severe sepsis and 90-day mortality.


RESULTS
A total of 583 patients developed severe sepsis (31%), of whom 149 died (26%). Systemic cytokine level elevation occurred in 82% of all subjects with CAP. Mean cytokine concentrations were highest at presentation, declined rapidly over the first few days, but remained elevated throughout the first week, beyond resolution of clinical signs of infection. Cytokine levels were highest in fatal severe sepsis and lowest in CAP with no severe sepsis. Unbalanced (high/low) cytokine patterns were unusual (4.6%) and not associated with decreased survival. Highest risk of death was with combined high levels of the proinflammatory IL-6 and anti-inflammatory IL-10 cytokine activity (hazard ratio, 20.5; 95% confidence interval, 10.8-39.0) (P<.001).


CONCLUSIONS
The circulating cytokine response to pneumonia is heterogeneous and continues for more than a week after presentation, with considerable overlap between those who do and do not develop severe sepsis. Unbalanced activation is uncommon, and mortality is highest when both proinflammatory and anti-inflammatory cytokine levels are high.
Kellum
John A
JA
Department of Critical Care Medicine, University of Pittsburgh School of Medicine, 604 Scaife Hall, 3550 Terrace St, Pittsburgh, PA15261, USA.
Kong
Lan
L
Fink
Mitchell P
MP
Weissfeld
Lisa A
LA
Yealy
Donald M
DM
Pinsky
Michael R
MR
Fine
Jonathan
J
Krichevsky
Alexander
A
Delude
Russell L
RL
Angus
Derek C
DC
D000368:Aged; D015331:Cohort Studies; D017714:Community-Acquired Infections / Q000097:blood / Q000276:immunology; D005260:Female; D006801:Humans; D007249:Inflammation / Q000150:complications; D016753:Interleukin-10 / Q000097:blood*; D015850:Interleukin-6 / Q000097:blood*; D008297:Male; D018410:Pneumonia, Bacterial / Q000097:blood* / Q000276:immunology*; D018805:Sepsis / Q000097:blood* / Q000276:immunology*; D012720:Severity of Illness Index; D014409:Tumor Necrosis Factor-alpha / Q000097:blood*
D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10
JAMA. 2002 Aug 21;288(7):862-71
12186604
Crit Care Med. 1997 Jul;25(7):1115-24
9233735
Ann Intern Med. 1996 Oct 15;125(8):680-7
8849154
Arch Surg. 1998 Jan;133(1):94-100
9438767
N Engl J Med. 1999 Jan 21;340(3):207-14
9895401
Crit Care Med. 2001 Apr;29(4):880-6
11373487
Intensive Care Med. 2003 Mar;29(3):368-77
12536269
Crit Care Med. 2003 Apr;31(4):1250-6
12682500
N Engl J Med. 2006 Sep 7;355(10):1018-28
16908486
Crit Care Med. 1995 Aug;23(8):1313-5
7634799
N Engl J Med. 1997 Mar 27;336(13):912-8
9070471
Biometrics. 1982 Dec;38(4):963-74
7168798
Chest. 1993 Feb;103(2):565-75
8432155
J Chronic Dis. 1987;40(5):373-83
3558716
Am J Hum Genet. 2003 Mar;72(3):611-20
12587095
Crit Care Med. 1994 Nov;22(11):1738-46
7956276
JAMA. 1998 May 13;279(18):1452-7
9600479
N Engl J Med. 1988 Jun 9;318(23):1481-6
2835680
Crit Care Med. 1996 Feb;24(2):207-14
8605790
Intensive Care Med. 2001 Oct;27(10):1578-83
11685297
Crit Care Med. 1994 Nov;22(11):1720-8
7956274
Nature. 2002 Jul 11;418(6894):191-5
12110890
JAMA. 1994 Jun 15;271(23):1836-43
8196140
Crit Care Med. 2006 Feb;34(2):344-53
16424713
Crit Care Med. 2001 Jul;29(7):1303-10
11445675
Clin Diagn Lab Immunol. 2004 Jan;11(1):161-7
14715564
Psychol Methods. 2001 Mar;6(1):18-34
11285809
Crit Care Med. 1993 Nov;21(11):1635-42
8222677
Am J Respir Crit Care Med. 2005 Feb 1;171(3):242-8
15557131
N Engl J Med. 2003 Jan 9;348(2):138-50
12519925
Microbiol Immunol. 1979;23(2):71-85
379551
Crit Care Med. 2001 Jul;29(7 Suppl):S121-5
11445746
Crit Care. 2004 Apr;8(2):R82-90
15025782
Crit Care Med. 1992 Jun;20(6):864-74
1597042
JAMA. 1997 Feb 12;277(6):482-7
9020273
Intensive Care Med. 1993;19(4):227-31
7690053
Intensive Care Med. 1996 Jul;22(7):707-10
8844239
Crit Care Med. 2004 Nov;32(11):2173-82
15640628
Chest. 1991 Dec;100(6):1619-36
1959406
Crit Care Med. 1993 Sep;21(9):1287-95
8370291
Crit Care Med. 1999 Jul;27(7):1262-4
10446817
Crit Care Med. 1998 Apr;26(4):660-7
9559602
Nature. 2002 Dec 19-26;420(6917):846-52
12490957
JAMA. 1996 Aug 21;276(7):565-6
8709407
N Engl J Med. 1997 Jan 23;336(4):243-50
8995086
Crit Care Med. 1998 Dec;26(12 ):1963-71
9875905